Document 1109
 DOCN  M94A1109
 TI    Foscarnet decreases HIV viremia.
 DT    9412
 AU    Kaiser L; Perrin L; Hirschel B; Olmari M; Yerly S; Hopital cantonal,
       Geneva, Switzerland.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):207 (abstract no. PB0842). Unique
       Identifier : AIDSLINE ICA10/94371466
 AB    INTRODUCTION: Treatment of CMV retinitis with foscarnet decreases p24
       antigenemia and offers a survival advantage over ganciclovir. The aim of
       our study is to assess if foscarnet has any effect on viremia. METHOD:
       In 6 patients treated with foscarnet for CMV retinitis (CD4 2-79/mm3),
       viremia (quantitative RT-PCR, expressed as log RNA copies/ml serum) and
       p24 antigenemia were measured before and after 2 to 4 weeks of therapy.
       Other antiviral were stopped. RESULTS: After foscarnet, viremia (p =
       0.03) and p24 Ag (p = 0.04) decrease. TABULAR DATA, SEE ABSTRACT VOLUME.
       CONCLUSIONS: On foscarnet these 6 patients decreased HIV-viremia.
 DE    Cytomegalovirus Retinitis/DRUG THERAPY/MICROBIOLOGY
       Foscarnet/*THERAPEUTIC USE  Human  HIV Core Protein p24/ANALYSIS  HIV
       Infections/DRUG THERAPY/*MICROBIOLOGY  RNA, Viral/ANALYSIS  Viremia/DRUG
       THERAPY/*MICROBIOLOGY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).